View:
Download DOC
Download PDF
Download XLS

QuickLinks -- Click here to rapidly navigate through this document

UNITED STATES
SECURITIES AND EXCHANGE COMMISSION
Washington, D.C. 20549

SCHEDULE 13D

Under the Securities Exchange Act of 1934
(Amendment No.    )*

Inverness Medical Innovations, Inc.
(Name of Issuer)

Common Stock, par value $0.001 per share
(Title of Class of Securities)

46126P 10 6
(CUSIP Number)

Jose M. de Lasa
Abbott Laboratories
100 Abbott Park Road
Abbott Park, Illinois 60064-6049
(847) 937-8905
(Name, Address and Telephone Number of Person
Authorized to Receive Notices and Communications)

September 30, 2003
(Date of Event Which Requires Filing of this Statement)

        If the filing person has previously filed a statement on Schedule 13G to report the acquisition that is the subject of this Schedule 13D, and is filing this schedule because of Rule 13d-1(e), 13d-1(f) or 13d-1(g), check the following box.    o

        The information required on the remainder of this cover page shall not be deemed to be "filed" for the purpose of Section 18 of the Securities Exchange Act of 1934 ("Act") or otherwise subject to the liabilities of that section of the Act but shall be subject to all other provisions of the Act (however, see the Notes).

CUSIP No. 46126P 10 6   13D   Page 1 of 1 Pages

1   NAMES OF REPORTING PERSONS
I.R.S. IDENTIFICATION NOS. OF ABOVE PERSONS (ENTITIES ONLY)
Abbott Laboratories
I.R.S. Identification No. 36-0698440
2   CHECK THE APPROPRIATE BOX IF A MEMBER OF A GROUP   (a)  o
                (b)  o
3   SEC USE ONLY

 		           
4   SOURCE OF FUNDS
OO
5   CHECK BOX IF DISCLOSURE OF LEGAL PROCEEDINGS IS REQUIRED PURSUANT TO ITEM 2(d) OR 2(e)
                o
6   CITIZENSHIP OR PLACE OF ORGANIZATION
Illinois

NUMBER OF
SHARES
 
7
 
SOLE VOTING POWER
1,550,933
 
 
BENEFICIALLY  
OWNED BY
EACH		   8   SHARED VOTING POWER
0		    
REPORTING  
PERSON
WITH		   9   SOLE DISPOSITIVE POWER
1,550,933		    
       
        10   SHARED DISPOSITIVE POWER
0		    
11   AGGREGATE AMOUNT BENEFICIALLY OWNED BY EACH REPORTING PERSON
1,550,933
12   CHECK BOX IF THE AGGREGATE AMOUNT IN ROW (11) EXCLUDES CERTAIN SHARES    
                o
13   PERCENT OF CLASS REPRESENTED BY AMOUNT IN ROW (11)
8.1%
14   TYPE OF REPORTING PERSON
CO

2


Item 1.    Security and Issuer

        This statement relates to shares of the common stock, par value $0.001 per share (the "Inverness Common Stock"), of Inverness Medical Innovations, Inc. ("Inverness"), a Delaware corporation, whose principal executive offices are located at 51 Sawyer Road, Suite 200, Waltham, Massachusetts 02453.


Item 2.    Identity and Background

        (a)–(c), (f)    This Schedule 13D is being filed by Abbott Laboratories, a corporation organized and existing under the laws of the State of Illinois ("Abbott"). Abbott's principal business is the discovery, development, manufacture and sale of a broad and diversified line of health care products. Abbott's principal office is located at 100 Abbott Park Road, Abbott Park, Illinois 60064-6049.

        The names, citizenship, business addresses, present principal occupation or employment and the name, and the principal business and address of any corporation or other organization in which such employment is conducted of the directors and officers of Abbott are as set forth in Exhibit 1 hereto and incorporated herein by this reference.

        (d) and (e)    During the last five years, neither Abbott nor, to the best knowledge of Abbott, any person listed on Exhibit 1, has been (i) convicted in a criminal proceeding (excluding traffic violations and similar misdemeanors) or (ii) a party to a civil proceeding of a judicial or administrative body of competent jurisdiction and as a result of such proceeding has been or is subject to a judgment, decree or final order enjoining future violations of, or prohibiting or mandating activities subject to, federal or state securities laws or finding any violation with respect to such laws.


Item 3.    Source and Amount of Funds or Other Consideration

        Pursuant to the Asset Purchase Agreement dated as of September 30, 2003 among Inverness, Inverness Medical Switzerland GMBh, Morpheus Acquisition Corp. and Morpheus Acquisition LLC (collectively, the "Inverness Buyers") and Abbott (the "Purchase Agreement"), the Inverness Buyers purchased certain assets and liabilities relating to Abbott's Fact plus®, Signify® and Abbott TestPack® product lines (the "Transaction"). A portion of the consideration paid by the Inverness Buyers to Abbott consisted of 1,550,993 shares of Inverness Common Stock (the "Shares").


Item 4.    Purpose of Transaction

        As disclosed in Item 3, Abbott acquired the Shares as partial consideration for the Transaction pursuant to the terms of the Purchase Agreement.

        (a)–(j)    Abbott intends to monitor its interests in Inverness on an ongoing basis and to take such measures as it deems appropriate from time to time in furtherance of such interests. Abbott may from time to time acquire additional shares of Inverness Common Stock, dispose of some or all of the shares of Inverness Common Stock then beneficially owned by it, discuss Inverness' business, operations, or other affairs with Inverness' management, board of directors, shareholders or others or take such other actions as Abbott may deem appropriate. Notwithstanding the foregoing, except as described in this Item 4 and in Item 6, Abbott has no present plan or proposal which relates to or would result in any of the matters referred to in Items (a) through (j) of Item 4 of Schedule 13D of the Securities and Exchange Commission. Abbott does, however, reserve the right to adopt such plans or proposals subject to compliance with applicable regulatory requirements.


Item 5.    Interest in Securities of the Issuer

        (a)   The Shares represent approximately 8.1% of the outstanding shares of the Inverness Common Stock. The calculation of the foregoing percentage is based on 17,675,244 shares of Inverness Common Stock outstanding as of September 26, 2003, as disclosed by Inverness in the Purchase Agreement.

        (b)   Abbott has the sole power to vote or to direct the vote and the sole power to dispose or to direct the disposition of the Shares.

        (c)   Except as described herein, there have been no transactions by Abbott or the persons whose names are listed on Exhibit 1 in securities of Inverness during the past sixty days.

3


        (d)   No one other than Abbott is known to have the right to receive or the power to direct the receipt of dividends from, or the proceeds from a sale of, the Shares.

        (e)   Not applicable.


Item 6.    Contracts, Arrangements, Understandings or Relationships with Respect to Securities of the Issuer

        The information set forth in Items 3 and 4 of this statement is hereby incorporated by this reference. Reference is made to the full text of the Purchase Agreement and the Registration Rights Agreement, dated as of September 30, 2003, between Inverness Medical Innovations, Inc. and Abbott Laboratories, each of which is annexed hereto as Exhibits 2 and 3, respectively, and incorporated herein by reference. To Abbott's knowledge, except as otherwise described in this Schedule 13D, there are no contracts, arrangements, understandings or relationships among the persons named in Item 2 and any other person, with respect to any securities of Inverness.


Item 7.    Material to be Filed as Exhibits

4


SIGNATURE

        After reasonable inquiry and to the best of my knowledge and belief, I certify that the information set forth in this statement is true, complete and correct.

Date: October 10, 2003      

 
 
 
/s/  THOMAS C. FREYMAN      
    Name: Thomas C. Freyman
    Title: Senior Vice President, Finance and Chief Financial Officer

5



QuickLinks

SIGNATURE

QuickLinks -- Click here to rapidly navigate through this document


EXHIBIT 1


Information Concerning Officers and
Directors of Abbott Laboratories

The current corporate officers and directors of Abbott Laboratories are listed below. The address of Abbott Laboratories is: Abbott Laboratories, 100 Abbott Park Road, Abbott Park, Illinois 60064-6049. Abbott Laboratories does not consider all of its corporate officers to be executive officers as defined by the Securities Exchange Act of 1934 or Releases thereunder. Unless otherwise indicated, all positions set forth below opposite an individual's name refer to positions within Abbott Laboratories, and, where applicable, the business address listed for each individual not principally employed by Abbott Laboratories is also the address of the corporation or other organization which principally employs that individual.

NAME
   POSITION/PRESENT PRINCIPAL
OCCUPATION OR EMPLOYMENT AND
BUSINESS ADDRESS
   CITIZENSHIP
CORPORATE OFFICERS        
Miles D. White1   Chairman of the Board and Chief Executive Officer and Director   U.S.A.

Jeffrey M. Leiden1
 
President and Chief Operating Officer, Pharmaceutical Products Group and Director
 
U.S.A.

Richard A. Gonzalez1
 
President and Chief Operating Officer, Medical Products Group and Director
 
U.S.A.

Christopher B. Begley1
 
Senior Vice President, Hospital Products
 
U.S.A.

Jose M. de Lasa1
 
Senior Vice President and General Counsel
 
U.S.A.

William G. Dempsey1
 
Senior Vice President, Pharmaceutical Operations
 
U.S.A.

Gary L. Flynn1
 
Senior Vice President, Ross Products
 
U.S.A.

Thomas C. Freyman1
 
Senior Vice President, Finance and Chief Financial Officer
 
U.S.A.

Greg W. Linder1
 
Vice President and Controller
 
U.S.A.

Guillermo A. Herrera1
 
Senior Vice President, International Operations
 
Colombia

Joseph M. Nemmers, Jr.1
 
Senior Vice President, Diagnostic Operations
 
U.S.A.

Thomas M. Wascoe1
 
Senior Vice President, Human Resources
 
U.S.A.

Lance B. Wyatt1
 
Senior Vice President and President, Global Pharmaceutical Manufacturing
 
U.S.A.

John Arnott
 
Vice President, Hospital Products Business Sector
 
United Kingdom

Catherine V. Babington
 
Vice President, Investor Relations and Public Affairs
 
U.S.A.

Michael G. Beatrice
 
Vice President, Corporate Regulatory and Quality Science
 
U.S.A.

Oliver Bohuon
 
Vice President, European Operations
 
France

Charles M. Brock
 
Vice President, Chief Ethics and Compliance Officer
 
U.S.A.

William E. Brown, III
 
Vice President, Diagnostic Assays and Systems Development
 
U.S.A.

Douglas C. Bryant
 
Vice President, Diagnostics Commercial Operations, Europe, Africa and Middle East
 
U.S.A.

Thomas F. Chen
 
Vice President, Pacific, Asia, and Africa Operations
 
U.S.A.

Jaime Contreras
 
Vice President, Diagnostic Commercial Operations, Latin America
 
Mexico

Michael J. Collins
 
Vice President, Diagnostics Commercial Operations, U.S. and Canada
 
U.S.A.
         

Thomas H. Dee
 
Vice President, Internal Audit
 
U.S.A.

Edward J. Fiorentino
 
Vice President, MediSense Products
 
U.S.A.

Stephen R. Fussell
 
Vice President, Compensation and Development
 
U.S.A.

Mark F. Gorman
 
Vice President, Ross Products, Medical Nutritionals
 
U.S.A.

Robert B. Hance
 
Vice President, Vascular Devices
 
U.S.A.

Terrence C. Kearny
 
Vice President and Treasurer
 
U.S.A.

James J. Koziarz
 
Vice President, Hepatitis/Retrovirus Research and Development and Assay Technical Support, Diagnostic Products
 
U.S.A.

John C. Landgraf
 
Vice President, Operations, Diagnostic Products
 
U.S.A.

Elaine R. Leavenworth
 
Vice President, Government Affairs
 
U.S.A.

Gerald Lema
 
Vice President, Diagnostics Operations, Asia and Pacific
 
U.S.A.

John M. Leonard
 
Vice President, Global Pharmaceutical Development
 
U.S.A.

Holger Liepmann
 
Vice President, Japan Operations
 
Germany

Richard J. Marasco
 
Vice President, Ross Products, Pediatrics
 
U.S.A.

Heather L. Mason
 
Vice President, Pharmaceutical Products, Specialty Operations
 
U.S.A.

P. Loreen Mershimer
 
Vice President, Hospital Products Business Sector
 
U.S.A.

Edward L. Michael
 
Vice President and President, Molecular Diagnostics
 
U.S.A.

Karen L. Miller
 
Vice President, Information Technology
 
U.S.A.

Sean Murphy
 
Vice President, Global Licensing/New Business Development
 
U.S.A.

Daniel W. Norbeck
 
Vice President, Global Pharmaceutical Discovery
 
U.S.A.

Edward A. Ogunro
 
Vice President, Hospital Products Research and Development, Medical and Regulatory Affairs
 
 

Roberto Reyes
 
Vice President, Latin America and Canada
 
Colombia

Laura J. Schumacher
 
Vice President, Secretary and Deputy General Counsel
 
U.S.A.

AJ J. Shoultz
 
Vice President, Taxes
 
U.S.A.

Mary T. Szela
 
Vice President, Pharmaceutical Products, Primary Care Operations
 
U.S.A.

James L. Tyree
 
Vice President, Global Licensing/New Business Development
 
U.S.A.

Steven J. Weger, Jr.
 
Vice President, Corporate Planning and Development
 
U.S.A.
         

Susan M. Widner
 
Vice President, Abbott HealthSystems
 
U.S.A.
1
Pursuant to Item 401(b) of Regulation S-K, Abbott has identified these persons as "executive officers" within the meaning of Item 401(b).

NAME
   POSITION/PRESENT PRINCIPAL
OCCUPATION OR EMPLOYMENT AND
BUSINESS ADDRESS
   CITIZENSHIP
DIRECTORS        
Roxanne S. Austin   President and Chief Operating Officer DIRECTV
2230 E. Imperial Highway
El Segundo, California 90245		   U.S.A.

H. Laurance Fuller
 
Retired Co-Chairman,
BP Amoco, p.l.c.
c/o Primary Business Center
1111 E. Warrenville Road
Suite 257
Naperville, Illinois 60563
 
U.S.A.

Richard A. Gonzalez
 
Officer of Abbott
 
U.S.A.

Jack M. Greenberg
 
Retired Chairman and Chief Executive Officer
McDonald's Corporation
333 W. Wacker Drive
Suite 1015
Chicago, Illinois 60606
 
U.S.A.

Jeffrey M. Leiden
 
Officer of Abbott
 
U.S.A.

The Rt. Hon. Lord Owen CH
 
Physician, Politician, and Businessman
House of Lords
Westminster, London
SW1A OPW, England
 
United Kingdom

Boone Powell, Jr.
 
Retired Chairman
Baylor Health Care System
9209 Westview Circle
Dallas, Texas 75231
 
U.S.A.

Addison Barry Rand
 
Former Chairman and Chief Executive Officer
Avis Group
500 Woodbine Road
Stamford, Connecticut 06903
 
U.S.A.

Dr. W. Ann Reynolds
 
Director, Center for Community Outreach and Development
The University of Alabama at Birmingham
933 9th Street South, Room 503-A
Birmingham, Alabama 35294-2041
 
U.S.A.

Roy S. Roberts
 
Managing Director
Reliant Equity Investors
401 N. Michigan Avenue
Suite 550
Chicago, Illinois 60611
 
U.S.A.

William D. Smithburg
 
Retired Chairman and Chief
Executive Officer
The Quaker Oats Company
676 N. Michigan Avenue
Suite 3860
Chicago, Illinois 60611
 
U.S.A.
         

John R. Walter
 
Chairman Ashlin Management Company
401 N. Ahwahnee Road
Lake Forest, Illinois 60045
 
U.S.A.

Miles D. White
 
Officer Of Abbott
 
U.S.A.


QuickLinks

Information Concerning Officers and Directors of Abbott Laboratories